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Abstract
Background: Treatment of locally advanced oesophago-gastric adenocarcinoma usually entails neo-adjuvant
chemotherapy (NAC) and surgery. Surgery is associated with high morbidity and mortality. Cardiopulmonary reserve of
patients having major surgery is related to postoperative outcomes. Complications are associated with poorer quality of life
and may affect prognosis. Preventing complications may be beneficial to both of these and have cost implications.
Prehabilitation may improve recovery from surgery by increasing a patients’ fitness before surgery. Designing a potentially
cost and resource effective regimen which improves cardiopulmonary reserve may have a beneficial impact on patient
outcomes after surgery.
Methods: The ChemoFit study is a non-randomised, single-arm and single-centre pilot study designed to investigate the
feasibility of a home-based prehabilitation exercise intervention for patients receiving neoadjuvant treatment prior to
oesophago-gastric surgery. Forty patients will be recruited at a single high-volume centre. The simple, home-based exercise
intervention involves patients increasing their daily step-count during and after NAC and in the weeks leading up to surgical
resection of the cancer. Additionally, quality of life assessments (QLQ-C30 and QLQ-OG25), oncological treatment delivery
and participant perceptions of the study assessed by focus groups and questionnaires will be performed. The primary
outcomes are to assess feasibility of the exercise intervention. The secondary outcomes will evaluate changes in
cardiopulmonary reserve, sarcopenia and fat composition.
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Discussion: It is anticipated that during an important teachable moment, the diagnosis and treatment of cancer, our
patients will be open to the possibility of improving their fitness during chemotherapy and before major cancer surgery.
It is possible that the negative impact of NAC on cardiopulmonary fitness could be prevented by implementing a home-
based prehabilitation programme during and after NAC, prior to surgery for oesophago-gastric adenocarcinoma.
Trial registration: This study has been approved by the Health Research Authority (REC 18/WA/0427). Newcastle upon
Tyne Hospitals NHS Foundation Trust (NUTH) will act as the study sponsor and the work is funded by a grant awarded by
The Jon Moulton Charitable Foundation, supported by a research post funded by the Sir Bobby Robson Foundation. Trial
registration: Clinicaltrials.gov, NCT04194463. Registered 11th December 2019—retrospectively registered, https://
clinicaltrials.gov/ct2/show/NCT04194463.
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Introduction
Curative treatment of locally advanced oesophago-
gastric adenocarcinoma usually entails neo-adjuvant
chemotherapy (NAC) followed by surgery and then post-
operative adjuvant chemotherapy. Multimodal therapy
has been shown to be superior to surgery alone [1, 2].
This type of major surgery is unfortunately associated
with high morbidity and mortality [3, 4]. It has been
shown that cardiopulmonary fitness prior to major sur-
gery is related to postoperative outcomes [5]. Previous
work has demonstrated a significant and sustained re-
duction in fitness during NAC given for oesophago-
gastric cancer, which not only affects daily activities and
quality of life, but also decreases the physical reserve of
the patient before they undergo major surgery [6, 7].
Both a reduction in objective cardiopulmonary reserve,
measured by cardiopulmonary exercise testing (CPET),
and reduction in muscle mass (sarcopenia) on CT scan
analysis in the interval between commencing chemo-
therapy and undergoing surgery has previously been ob-
served [7]. Complications of major surgery are
associated with poorer quality of life in the short-term
and worse prognosis [8]. Further, they can delay or pre-
vent the administration of post-operative chemotherapy,
which may impact on disease recurrence. Preventing
these complications may improve surgical outcomes, pa-
tient health and survival from oesophago-gastric cancer.
In addition, exercise may have beneficial effects on im-
proving immune surveillance and reducing inflamma-
tion; reversing abnormalities that may be associated with
tumour recurrence and growth [9].
High-intensity exercise interventions have already
demonstrated the ability to prevent the decline in health
observed in other patient groups undergoing chemother-
apy [10, 11]. These programmes require a large financial
investment, time commitment and the use of complex
hospital resources. In a wide geographical area, attending
hospital-based interventions can be challenging to im-
plement, particularly when patients are unable to travel
due to the impact of their treatment, and the cost of
travelling long distances. To help overcome these bar-
riers, we have developed a home-based exercise inter-
vention, which could be utilised by a large number of
patients at any one time. The aim of the pilot study is to
assess the feasibility, acceptability and safety of this
intervention on a small group of patients. Further, the
impact of such a regimen on cardiorespiratory fitness
and sarcopenia will be assessed and its effect on bio-
markers measuring immune function and frailty ex-
plored. It is hoped that the data from this study will help
to inform future randomised studies into the benefit of
exercise programmes.
Methods
Study design
This is a prospective, single-group, single-centre pilot
study investigating the feasibility and acceptability of a
home-based exercise intervention during oncological
treatment of patients presenting with operable advanced
adenocarcinoma of oesophagus, gastro-oesophageal
junction and stomach. Patients will be invited to partici-
pate in the study which involves provision of a home-
based exercise intervention before, during and after
NAC, and in the weeks leading up to surgical resection
of the cancer.
Study aims
The primary aim of the pilot study is to assess the feasi-
bility of the home-based exercise intervention. This will
be assessed by the measurement of the recruitment rate,
completion rate and individual compliance with the
intervention (i.e. do patients perform the exercise, en-
gage with telephone support and record their activity
levels in accordance with protocol).
The secondary aim of this study involves the prelimin-
ary assessment of benefit to patients’ physiology and
quality of life related to the exercise intervention. Results
will be used to inform the design of a larger scale rando-
mised controlled trial evaluating the impact of an exer-
cise regimen on patients’ cardiopulmonary fitness,
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sarcopenia, quality of life and potentially postoperative
outcomes such as morbidity and length of hospital stay.
The ChemoFit study (as a part of the secondary out-
comes) will aim to assess cardiopulmonary fitness as
measured using cardiopulmonary exercise testing
(CPET), changes in muscle mass (sarcopenia) as mea-
sured using computed tomography (CT), handgrip
strength and quality of life utilising QLQ-C30 and QLQ-
OG25 questionnaires [12, 13]. Patient’s physical activity
will be measured by daily step counts using waist-worn
pedometers, which serve as the method of quantifying
activity levels and will help with prescribing home-based
activity increases. The oncology treatment will be
assessed by recording chemotherapy dose reduction and
delays, percentage of planned chemotherapy delivered
and admissions to hospital with chemotherapy induced
toxicity. Acceptability of the intervention will be assessed
with patients taking part in the study by eliciting their
views and experiences via focus group discussions. The
qualitative component of this feasibility study will obtain
participants’ views and experiences of the intervention
via focus groups, including what they perceive to be bar-
riers and facilitators to using it in order to assess accept-
ability. The purpose of this qualitative component is to
inform the design of future studies and there is no plan
to include acceptability or any other qualitative work in
future designs. Up to five focus group discussions will be
conducted by a researcher using a topic guide containing
questions designed to address the objectives of the
study.
It is not intended to use any data obtained from the
ChemoFit study in future randomised controlled trials.
Inclusion and exclusion criteria
Patients with locally advanced adenocarcinoma (T3+,
T1/2 N+) [14] of the oesophagus, oesophago-gastric
junction or stomach and a planned NAC regimen in-
cluding the locally used ECX, ECX variant [1] or FLOT
[15] regimens will be eligible to participate in the study.
Participants 18 years of age or older and able to consent
to the study and carry out the planned intervention and
CPET tests required in the protocol will be invited to
participate.
Exclusion criteria are patients treated with neo-
adjuvant radiotherapy or chemoradiotherapy, patients in
whom CPET is contraindicated [16], and patients with
inoperable tumours.
Patient selection and consent process
Patients will be identified during the multidisciplinary
cancer staging process at the Northern Oesophago-
gastric Unit. Suitable patients, who meet the eligibility
criteria, will be provided with a patient information sheet
(PIS) explaining the study. They will be consented for
the study after the finalised oncological treatment plan
has been agreed by the multidisciplinary team and dis-
cussed with the patient. By providing a PIS early in the
staging process patients will have sufficient time to con-
sider their participation in the study and ask questions.
All eligible patients will be approached, and participation
will be voluntary: they will be able to withdraw consent
at any point during the study. Patients who have not
agreed to take part in the study by the time they start
their first chemotherapy session will not be eligible to
participate.
During the first study enrolment meeting, informed,
written consent will be obtained prior to any study pro-
cedures and each patient will be asked to complete base-
line QLQ-C30 and QLQ-OG25 quality of life
questionnaires [12, 13]. The handgrip strength of their
dominant hand will be measured using grip strength
dynamometer (T.K.K. 5101 GRIP-D, Takei scientific in-
struments Co., Ltd., Japan). Participants will be provided
with a simple, easy to use pedometer (Walking style One
2.1, Omron Healthcare UK Ltd., UK), resistance band
(BodyMax resistance tube, BodyMax Ltd., UK) and exer-
cise diaries. They will receive information about what
the exercise intervention involves and taught how to use
the pedometer, resistance band and exercise diaries.
Intervention
Baseline measurement
Once enrolled into the study, participants will immedi-
ately enter a 1-week period of monitoring using a ped-
ometer to record their habitual physical activity (daily
step count). This initial period will be used to establish a
baseline physical activity level for each participant and
will be used to calculate each individual’s median daily
step count. Baseline CPET and CT data will be collated
at this point. Both CPET and CT data will have been
performed as part of routine clinical care during the
multidisciplinary team (MDT) staging process (Fig. 1).
The exercise intervention
The exercise intervention will start immediately following
completion of the 1-week period of baseline monitoring.
The intervention will continue during chemotherapy and
afterwards in the time period between the end of chemo-
therapy and the planned surgical resection. The interven-
tion will be personalised to each patient based on their
baseline level of activity (as recorded by a pedometer during
the first week of observation), age, general health, motiv-
ation, and social circumstances with the aim of achieving
the greatest improvement in their cardiopulmonary fitness.
The exercise intervention will aim to achieve an in-
crease in daily step count of 2000 steps per day, 7 days
per week [17]. This increase in physical activity (step
count) will be achieved by walking or jogging at
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moderate intensity for a target of 30 min per day, each
day (this is one ‘bout‘ of moderate intensity exercise)
[18]. Participants will be instructed on how to achieve
moderate intensity physical activity using the modified
Borg rating of perceived exertion (RPE) scale (0–10)
aiming to achieve an RPE level between 3 and 4 (moder-
ate to somewhat strong exertion) [19]. This will ensure
that the intensity at which these 30-minute bouts of
physical activity are maintained throughout the entire
exercise period. Patients will be asked to record their
daily step count at the end of every day and the RPE for
the 30-min bout of exercise. The Borg scale will be used
as a tool to describe levels of home-based physical activ-
ity throughout the study.
After the first week of the intervention, patients will
be contacted by a member of the research team; and
with the research team’s support they will be given the
option to maintain or to increase their step count fur-
ther if they feel that they have managed to achieve the
prescribed amount of steps in the previous week. The
same approach will be used after each week of the inter-
vention. The aim of this is to facilitate a participant-led
increase in daily physical activity based upon increasing
the daily step target. Participants will also be encouraged
to perform other physical activities like jogging, swim-
ming, cycling or group activities if they wish and feel
able to do so.
The participants’ progress will be monitored in a daily
diary entry.
After completion of NAC, a further enhanced increase
in the daily activity above the current physical activity
level will be implemented providing the patient is com-
fortable with this progression. The level of this increase
will be based on current progress and, as such will be
tailored to individual needs and circumstances. This in-
cremental period will start 7 days after the last Capecita-
bine tablet (given as part of the chemotherapy) and
continue until the end of the study and the last study
visit.
Strengthening exercises
Strengthening exercises will be performed alongside the
exercise intervention. Strengthening exercises will be
performed every day, 7 days per week, and will start after
the end of the baseline observation week has been com-
pleted. The patients will be taught how to perform two
Fig. 1 Consort diagram of the study
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sets of five simple exercises (sit to stand/wall squat, bi-
ceps curl, upright row, leg abduction, wall press), each
for 1-min duration by a member of the research team.
This equates to 10 min of strengthening exercise in total
each day. Exercises have been selected to strengthen
major body muscle groups. Each exercise will be pre-
scribed at two levels of intensity in order to tailor them
to individual fitness levels. A booklet demonstrating the
correct performance of the strengthening exercises will
be given to each patient to take home. They will receive
weekly telephone calls to encourage and reinforce the
importance and conduct of these strengthening
exercises.
Interim analysis of step-based regimen
Once the first 10 participants have each completed the
first week of the exercise regimen during NAC, we will
perform an interim analysis of their achieved daily step
count during this first week. If ≥ 60% of participants
have not achieved the prescribed daily step count for at
least 5 days of this week, then we will lower the incre-
ment in steps described within the protocol. We will
change this initial increment to 1000 steps above base-
line daily step count for all participants recruited after
the interim analysis.
Conversely, if ≥ 80% of participants have achieved the
prescribed daily step count for all 7 days of the first
NAC exercise week, we will increase our first increment
to 3000 steps above baseline daily step count for all par-
ticipants recruited after the interim analysis.
This strategy has been chosen to ‘fine adjust’ our initial
step increment after the first observation week as it is
difficult to predict how demanding this increment is go-
ing to be for patients, especially in the context of starting
chemotherapy treatment. There is no current evidence
to guide this decision. Based on the findings from the
Active-at-Home HF pilot study in stable chronic heart
failure patients, we replicated the same physical activity
steps/day in our patients, i.e. an increase of 2000 steps/
day from baseline physical activity [17].
Weekly telephone reporting, reinforcement and
encouragement
A member of the research team will contact each study
participant once per week by telephone in order to pro-
vide support, reinforce the aims of programme and re-
iterate the benefits, monitor activities and exercises,
collect the previous week’s data and provide positive
feedback. Participants will be encouraged to reflect upon
the previous weeks achievements and discuss any prob-
lems or factors which may have inhibited progress with
a view to identifying strategies to overcome these prob-
lems, where possible. These will be recorded by the re-
search team. Patients will be given the opportunity to
increase their daily target for the next week if they feel
that this is achievable or appropriate.
Completion of the exercise intervention
The end of the study period is defined as the last full
week of exercise before surgery. Participants will
complete an end of study CPET, hand grip strength
measurement, blood sampling and quality of life ques-
tionnaires during the 2 weeks prior to their scheduled
surgery. A CT scan, which is performed as part of rou-
tine clinical care prior to the surgery, will be used for
comparison with the initial CT scan to measure
sarcopenia.
Cardiopulmonary exercise testing
The end of study CPET will be performed in accordance
with the American Thoracic Society/American College
of Chest Physicians guidelines [20]. Patients will perform
a symptom-limited continuous ramped test on cycle erg-
ometer (Ergoselect 200, Ergoline GmbH, Germany).
Metabolic gas analysis will be conducted via the meta-
bolic cart (Ultima Series, MGC Diagnostics, USA). CPET
data will be analysed using the Breeze SuiteTM software
(Ultima Series, MGC Diagnostics, USA). This will be
performed initially alongside staging investigations,
which is part of normal routine clinical care and add-
itionally prior to surgery as part of the study protocol.
Usual clinical care during the study
All participants enrolled in the study will be managed
according to the standardised patient pathway that
already exists. Patients are reviewed by the surgical
team and counselled with regard to the treatment op-
tions that are available. Those patients that are strug-
gling nutritionally are then reviewed by one of two
specialist upper gastrointestinal dietitians. If patients
are unable to manage sufficient calorie input without
assistance, they may have a naso-enteric feeding tube
placed or a feeding jejunostomy so that they receive
sufficient calories.
Study outcomes
The primary and secondary outcomes are defined in
Table 1 and Table 2.
Statistical considerations
Estimation of sample size
A sample size of 40 participants has been selected in ac-
cordance with published guidance for pilot feasibility stud-
ies [22, 23]. Further, this was considered to be an
achievable number of patients to recruit within the 12
months. Approximately 130 patients undergo oesophago-
gastric resections each year for cancer at the Northern
Oesophago-Gastric Unit, Royal Victoria Infirmary,
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Newcastle upon Tyne. It is estimated that 70% will be eli-
gible to take part in the study (i.e. will receive preoperative
chemotherapy for adenocarcinoma) [24]. All of these pa-
tients will be invited to participate, and it is hoped that en-
rolment will reach approximately 85–95% as already
demonstrated by other prehabilitation studies, which
employed home-based interventions [25–27]. In this re-
spect, a sample size of 40 also realistically represents the
number of patients that might be expected to be recruited
in a year. In a recent study investigating CPET testing
after chemotherapy only one participant of 32 recruited
participants withdrew consent during the study (3%) [24]:
this group of cancer patients is motivated and compliant.
It is expected that it will take 12 months to recruit 40 pa-
tients to this study.
Statistical analysis
Analyses will be conducted using SPSS, version 24.0
(IBM Corp., USA). The primary outcomes will be de-
scribed using simple descriptive statistics. Characteristics
of the patients will be described as the mean (SD) or
median (IQR) for continuous data and as the number of
patients and percentages for categorical data. Compari-
son between pre and post intervention data will be ana-
lysed using Student’s t test or Mann-Whitney’s test for
continuous data. The effect of the intervention will be
estimated using 75% confidence intervals.
Qualitative data analysis
Focus group discussions will be audio recorded and
transcribed verbatim. Data from each transcript will be
analysed by two researchers initially gaining familiarisa-
tion with the texts. These will then be coded by the two
researchers to identify initial themes. Once all the data
has been coded and initial themes identified, there will
be further discussion to determine main themes and
sub-themes. Following this the original data will be
revisited to consider it in relation to the themes pro-
duced. These themes will then be named and will help
provide a final thematic grip [28].
Patient and public involvement
Survivors of oesophago-gastric cancer previously treated
at the Northern Oesophago-gastric Unit were approached
during a cancer support group meeting. The hypothesis
and design of the study was presented, and open discus-
sion ensued; thereafter, the patients were also asked to
comment on the study by completing questionnaires.
They were asked to reflect on their experience in relation
to the proposed study design. Themes from the discussion
were recorded by one investigator (JC) and grouped into
areas of agreement and comment. All the patients (100%)
agreed that if they had been in the position of awaiting
surgery again, they would have liked to participate in an
exercise study. The additional time required attending
extra tests, sessions and time needed to spend to comply
with the study protocol was found to be acceptable by all
respondents (100%).
In a second study six patients recovering from re-
cent surgery for oesophageal and stomach cancer
were approached on a postoperative surgical ward at
the RVI, Newcastle upon Tyne. The study was intro-
duced to them, and they were asked about their fit-
ness levels prior to diagnosis, during chemotherapy
and in the period immediately before surgery. Their
opinion was sought regarding the feasibility of this
study and about their willingness to participate if they
had the opportunity to choose this programme prior
to their surgery.
Table 1 The primary outcomes of the study
Primary outcome
measures
Definition Success
threshold
Recruitment rate Proportion of all patients approached
who meet the eligibility criteria and
agree to enter the study
50%
Completion rate Proportion of all patients that enter
the study that remain participants
at the end of the defined study
period
75%
Compliance Percentage of intervention days
when the patient was wearing
his/her pedometer, was
contactable every week and was
recording his/her daily step count
75%
Table 2 The secondary outcomes of the study
Secondary outcome
measures
CPET Change in VO2 peak (ml/min/kg), change
in VO2 at AT (ml/min/kg) and change in
FEV1 prior and post intervention
Sarcopenia Change in amount of L3 level skeletal
muscle area determined on CT scan by
methodology described by Perthen et al.
[21], change in fat composition and
volume measured by CT scan and
change in grip strength pre and post
intervention
Exercise intervention Change of step count throughout the
intervention
Oncological
treatment
Number of patients with dose reductions
or who terminate chemotherapy early,
percentage of planned chemotherapy
delivered, admissions to hospital with
chemotherapy induced toxicity
Quality of life Change of score on validated quality of
life questionnaires QLQ-C30 and
QLQ-OG25 pre and post intervention
Acceptability Qualitative evidence generated from focus
group discussions with participants
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The results of the study will be shared with our
oesophago-gastric cancer survivors again during cancer
support group meeting once these are available.
Discussion
It is anticipated that during an important teachable mo-
ment, the diagnosis and treatment of cancer, our pa-
tients will be open to the possibility of improving their
fitness during chemotherapy and before major cancer
surgery. Having previously demonstrated that fitness de-
clines during oncological treatment we hope an exercise
intervention that maintains or improves fitness could
lead to better patients’ outcomes in the future. It is pos-
sible that the negative impact of NAC on cardiopulmo-
nary fitness could be prevented by implementing a
home-based prehabilitation programme during and after
NAC, prior to surgery for oesophago-gastric adenocar-
cinoma. It is hypothesised that exploring a simple and
low-cost alternative to high-impact, high-intensity, high-
cost regimens could revolutionise the routine clinical
care of our patients leaving them better prepared for the
stress and morbidities associated with oesophago-gastric
cancer surgery. This is a non-randomised, single cohort,
unblinded, single-centre feasibility study with a small
sample size. This design could lead to potential selection
bias however the aim is to take a pragmatic approach
which will allow patients to be recruited over a 1-year
period and help inform a larger scale randomised con-
trol trial.
Trial status
Recruitment to the ChemoFit started on 28.2.2019. The
study is being conducted according to version 1.0 of the
ChemoFit study protocol from 25 October 2018.
Abbreviations
NAC: Neo-adjuvant chemotherapy; NUTH: Newcastle upon Tyne Hospitals
NHS Foundation Trust; CPET: Cardiopulmonary exercise testing;
CT: Computed tomography; PIS: Patient information sheet; RPE: Rating of
perceived exertion; GCP: Good Clinical Practice
Authors’ contributions
JC is a research student and JC, RCFS and AG are the principal authors of
this research protocol. The wider research team have been involved in
specialist areas of design (AWP) and in the overall completion, review and
agreement to proceed with the protocol. SJC and KH present specialist
exercise regimen knowledge and strengthening exercise design and LA
provides expertise in health behaviour change, intervention development,
evaluation and qualitative research methods. The protocol has been
approved and agreed by all authors. The manuscript presented here has
been written by JC and then amended, approved and agreed with all
authors.
Funding
This work was supported by The Jon Moulton Foundation Charitable Grant
and a grant from the Sir Bobby Robson Fund.
Availability of data and materials
This is the study protocol of the study which is still in progress therefore no
data are available at the moment. We intend to publish our results in peer-
reviewed journals and also at national and international conferences. Data
will be also summarised on clinicaltrials.gov. As a requirement of our grant
contract, the findings of this study will be presented to the charity funder.
Ethics approval and consent to participate
Approval was granted by the Health Research Authority on 16 January 2019
(REC 18/WA/0427). Newcastle upon Tyne Hospitals NHS Foundation Trust
(NUTH) acts as a study sponsor. This study is registered on Clinicaltrials.gov
(NCT04194463). Written informed consent will be obtained after patients
have been provided with a participant information sheet and had sufficient
time to consider their participation. We will ensure that patients understand
that their participation is voluntary: the decision to participate (or not) will
not affect a patients’ treatment in any way and they may withdraw from the
study at any time without providing the reason. The consent process will be
in accordance with Good Clinical Practice (GCP) guidance and local standard
operating procedures. Participants will also be fully informed about
requirements regarding data protection and direct access to their individual
data.
Competing interests
The authors declare that they have no competing interests.
Author details
1Northern Oesophago-gastric unit, Royal Victoria Infirmary, Newcastle upon
Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
2Translational and Clinical Research Institute, Faculty of Medical Sciences,
Newcastle University, Newcastle upon Tyne, UK. 3School of Medical
Education, Newcastle University, Newcastle upon Tyne, UK. 4Northern Centre
for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals NHS
Foundation Trust, Newcastle upon Tyne, UK. 5Cardiovascular Research,
Translational and Clinical Research Institute, Faculty of Medical Sciences,
Newcastle University, Newcastle upon Tyne, United Kingdom. 6Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
7Centre for Rehabilitation, Exercise and Sport Science, School of Health & Life
Sciences, Teesside University, Tees Valley, UK. 8The Liver Unit, Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
9Hepatology Research, Translational and Clinical Research Institute, Faculty of
Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
10Department of Anaesthesia and Critical Care, Royal Victoria Infirmary,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne,
UK.
Received: 5 February 2020 Accepted: 7 April 2020
References
1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results
of a randomized trial of surgery with or without preoperative
chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.
3. National Oesophago-Gastric Cancer Audit 2017 2017 [Available from:
https://www.nogca.org.uk/content/uploads/2017/12/NOGCA-Annual-
Report-2017.pdf.
4. Sinclair RCF, Phillips AW, Navidi M, Griffin SM, Snowden CP. Pre-operative
variables including fitness associated with complications after
oesophagectomy. Anaesthesia. 2017;72(12):1501–7.
5. Moran J, Wilson F, Guinan E, McCormick P, Hussey J, Moriarty J. Role of
cardiopulmonary exercise testing as a risk-assessment method in patients
undergoing intra-abdominal surgery: a systematic review. Br J Anaesth.
2016;116(2):177–91.
6. Jack S, West MA, Raw D, Marwood S, Ambler G, Cope TM, et al. The effect
of neoadjuvant chemotherapy on physical fitness and survival in patients
undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014;40(10):
1313–20.
7. Sinclair R, Navidi M, Griffin SM, Sumpter K. The impact of neoadjuvant
chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal
adenocarcinoma. Ann R Coll Surg Engl. 2016;98(6):396–400.
8. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ,
et al. Determinants of long-term survival after major surgery and the
Chmelo et al. Pilot and Feasibility Studies            (2020) 6:50 Page 7 of 8
adverse effect of postoperative complications. Ann Surg. 2005;242(3):326–41
discussion 41-3.
9. Ulrich CM, Himbert C, Holowatyj AN, Hursting SD. Energy balance and
gastrointestinal cancer: risk, interventions, outcomes and mechanisms. Nat
Rev Gastroenterol Hepatol. 2018.
10. West MA, Loughney L, Barben CP, Sripadam R, Kemp GJ, Grocott MP, et al.
The effects of neoadjuvant chemoradiotherapy on physical fitness and
morbidity in rectal cancer surgery patients. Eur J Surg Oncol. 2014;40(11):
1421–8.
11. West MA, Loughney L, Lythgoe D, Barben CP, Sripadam R, Kemp GJ, et al.
Effect of prehabilitation on objectively measured physical fitness after
neoadjuvant treatment in preoperative rectal cancer patients: a blinded
interventional pilot study. Br J Anaesth. 2015;114(2):244–51.
12. Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical
and psychometric validation of an EORTC questionnaire module, the EORTC
QLQ-OES18, to assess quality of life in patients with oesophageal cancer.
Eur J Cancer. 2003;39(10):1384–94.
13. Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, et al. Clinical
and psychometric validation of a questionnaire module, the EORTC QLQ-
OG25, to assess health-related quality of life in patients with cancer of the
oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer.
2007;43(14):2066–73.
14. TNM Classification of Malignant Tumours, 8th Edition: Wiley-Blackwell; 2016.
15. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin,
and docetaxel versus fluorouracil or capecitabine plus cisplatin and
epirubicin for locally advanced, resectable gastric or gastro-oesophageal
junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet.
2019;393(10184):1948–57.
16. Weisman I. ATS/ACCP Statement on Cardiopulmonary exercise testing.
American Journal of Respiratory and Critical Care Medicine. 2003;167(2):211–
77.
17. Okwose NC, Avery L, O'Brien N, Cassidy S, Charman SJ, Bailey K, et al.
Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised,
home-based physical activity intervention for chronic heart failure (Active-
at-Home-HF): a pilot study. Sports Med Open. 2019;5(1):45.
18. Physical activity guidelines: UK Chief Medical Officers' report.
19. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc.
1982;14(5):377–81.
20. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit
Care Med. 2003;167(2):211-77.
21. Perthen JE, Ali T, McCulloch D, Navidi M, Phillips AW, Sinclair RCF, et al.
Intra- and interobserver variability in skeletal muscle measurements using
computed tomography images. Eur J Radiol. 2018;109:142–6.
22. Sim J, Lewis M. The size of a pilot study for a clinical trial should be
calculated in relation to considerations of precision and efficiency. J Clin
Epidemiol. 2012;65(3):301–8.
23. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract. 2004;10(2):307–12.
24. Navidi M, Phillips AW, Griffin SM, Duffield KE, Greystoke A, Sumpter K, et al.
Cardiopulmonary fitness before and after neoadjuvant chemotherapy in
patients with oesophagogastric cancer. Br J Surg. 2018;105(7):900–6.
25. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, et al. Prehabilitation
versus rehabilitation: a randomized control trial in patients undergoing
colorectal resection for cancer. Anesthesiology. 2014;121(5):937–47.
26. Bousquet-Dion G, Awasthi R, Loiselle S, Minnella EM, Agnihotram RV,
Bergdahl A, et al. Evaluation of supervised multimodal prehabilitation
programme in cancer patients undergoing colorectal resection: a
randomized control trial. Acta Oncol. 2018;57(6):849–59.
27. Ngo-Huang A, Parker NH, Wang X, Petzel MQB, Fogelman D, Schadler KL,
et al. Home-based exercise during preoperative therapy for pancreatic
cancer. Langenbecks Arch Surg. 2017;402(8):1175–85.
28. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative
Research in Psychology. 2006;3(2):77–101.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Chmelo et al. Pilot and Feasibility Studies            (2020) 6:50 Page 8 of 8
